Market Overview

Axial Biotherapeutics Named a "Fierce 15" Biotech Company of 2017 by FierceBiotech


Axial Biotherapeutics, a biotechnology company building a unique class
of microbial-targeted therapeutics for neurological diseases, today
announced that it has been named by FierceBiotech as one of 2017's
Fierce 15 biotechnology companies, designating it as a promising and
innovative private biotech company whose research and development work
has helped to transform the industry.

"It is an honor to be a recipient of this year's FierceBiotech's Fierce
15 award," said David H. Donabedian, Ph.D., CEO and Co-Founder of Axial
Biotherapeutics. "The credit goes to our dedicated team and advisors who
have been working together to pioneer a new treatment path for
neurological diseases and disorders through targeting the gut microbiome
as well as building the company over the past year. This important
recognition is also a testament to the groundbreaking research of our
scientific co-founder Sarkis K. Mazmanian, Ph.D. which is the basis of
our lead programs in Autism Spectrum Disorders and Parkinson's Disease
and we are commited to bring this exciting approach into the clinic in
the near future."

The Fierce 15 award celebrates the spirit of being "fierce" –
championing innovation and creativity, even in the face of intense
competition. This is FierceBiotech's fifteenth annual Fierce 15
selection. Every year FierceBiotech evaluates hundreds of private
companies from around the world for its annual Fierce 15 list, which is
based on a variety of factors such as the strength of its technology,
partnerships, venture backers and a competitive market position.

About FierceBiotech
An internationally recognized daily
report reaching a network of more than 275,000 biotech and pharma
industry professionals, FierceBiotech provides subscribers with an
authoritative analysis of the day's top stories. Every business day,
FierceBiotech and its family of publications covers the waterfront in
drug development, from pre-clinical science to seed funding and venture
capital, through IPOs and licensing, clinical testing, regulatory
changes, M&A and beyond. Signup is free at

About Axial Biotherapeutics
Axial Biotherapeutics is a
biopharmaceutical company harnessing the link between the human gut
microbiome and the central nervous system to develop a new class of
biotherapeutics to improve the quality of life for people with
neurological diseases and disorders.

View Comments and Join the Discussion!